Disolf is a DLBS product that contains DLBS1033, a standardized protein fraction derived from Lumbricus rubellus through a patented extraction technology. It possesses eight major proteins with a molecular weight below 100 kDa, a specific pattern that gives DLBS1033 its unique characteristics, named LLP (Lumbricus Low molecular weight Proteins).
Disolf is indicated for antithrombotic and thrombolytic purposes and has been clinically proven to improve neurological function in acute ischemic stroke, with a similar safety profile compared with clopidogrel and aspirin. It is used as an adjunct to aspirin treatment, showing better clinical outcomes improvement compared to aspirin alone.
Disolf contains a precisely formulated dose of 490 mg of DLBS1033 in enteric-coated tablet form, designed to protect DLBS1033 against gastrointestinal enzymes, achieve the desired therapeutic effects, and ensure optimal results.
A Brief Introduction to Our Product
Disolf has mechanisms of action as an antithrombotic and thrombolytic agent. Its antithrombotic properties are attributed to its ability to inhibit platelet aggregation and fibrinogenolytic activity on α-, β-, and γ-chain of fibrinogen. The thrombolytic properties of DLBS1033 are demonstrated through its fast and long-acting fibrinolytic activity and its effective blood clot lysis activities. In addition, DLBS1033 has been shown to play an important role in downregulating inflammatory markers such as JAK1, STAT1, TNF-α, and NF-κβ, as well as reducing oxidative stress.
Product Functions
Earthworms have been widely used in Asia for several thousand years to treat various diseases. Historically, it was reported that enzymes secreted from the alimentary tract of earthworms could dissolve fibrin. Numerous studies have demonstrated that earthworms possess anti-thrombosis and thrombolytic activities, both in vitro and in vivo.
Disolf, which contains DLBS1033, a Lumbricus low molecular weight protein, has been shown to have anti-thrombosis activities due to its anti-platelet aggregation and fibrinogenolytic activity. The thrombolytic activity of DLBS1033 was demonstrated by clot lysis assays. Its direct fibrinolytic activity was also confirmed using the zymogram and fibrin disk methods.
In vitro studies demonstrated that DLBS1033 significantly reduced the percentage of blood aggregation. It also exhibited fibrinogenolytic activity on the α-, β-, and γ-chains of fibrinogen. The ex vivo study indicated that DLBS1033 prolonged blood clotting time, further confirming its antithrombotic properties.
Moreover, DLBS1033 has been shown to exert antiinflammatory action and inhibit the proliferation and migration of smooth muscle cells. It downregulated inflammatory markers, including JAK1, STAT1, TNFα, and NF-kB, as well as decreased vascular smooth muscle cell proliferation and migration. DLBS1033 also permitted plaque stabilization in the vasculature by downregulating the expression of matrix metalloproteinase-9 (MMP-9).
Several clinical studies have evaluated the safety and efficacy of DLBS1033. A randomized, double-blind, placebo-controlled cross-over, and fixed-dose study involving 19 healthy volunteers demonstrated that DLBS1033 is safe when administered at 490 mg three times daily, 30 minutes before meals. Throughout the study, no hemorrhagic symptoms were observed. The levels of hemostatic parameters—such as prothrombin time, thrombin time, activated partial thromboplastin time (aPTT), and fibrinogen levels—remained within the normal range. There were also no allergic symptoms, and no serious adverse events occurred during the study. Furthermore, DLBS1033 significantly reduced platelet aggregation compared to placebo.
Another open-label study focused on reducing carotid artery intima-media thickness (CCA-IMT) in atherosclerosis patients, showing a significant decrease after two and four weeks of DLBS1033 treatment, suggesting a potential reduction in cardiovascular event risk.
A separate randomized controlled study involving 126 acute ischemic stroke patients concluded that DLBS1033 had a comparable hemostatic profile (prothrombin time, thrombin time, aPTT, and fibrinogen levels) to aspirin and clopidogrel, which led to improved clinical outcomes, surpassing the improvements seen with traditional treatments.
Additionally, the preliminary, randomized, double-blind, and placebo-controlled study suggests that DLBS1033 could be a promising treatment for cerebrovascular diseases, including Peripheral Artery Disease (PAD). The study showed that DLBS1033 improved the Ankle-Brachial Index (ABI) in patients with intermittent claudication, offering hope for its potential in treating these conditions.
Insights and Discoveries
Dosage Instructions
Take one tablet three times a day, 30 to 60 minutes before meals.
If You Miss a Dose
Take it as soon as you remember. If it's almost time for your next dose, skip the missed one. Do not take extra medicine to make up the missed dose.
Contraindications
Patients with blood clotting disorders
Patients with allergic history of any components from bioactive protein fraction
Side Effects
No side effects have been reported. Considered as safe if taken at the recommended dosage.
Drug interaction
Caution for concomitant use with strong anti-platelet drugs.
Special warnings and precautions for use
Discontinue administration at minimum 2 weeks before/after surgery or follow the physician's instructions
Caution for use in patients with deep bleeding, ulcer, intracranial or intraspinal post-surgery, post-trauma, and other bleeding disorder conditions.
Combination with strong anti-platelet agents or three combination should take cautions
Not recommended for pregnant and breastfeeding women.
Recommendations for Safe Administration and Use of Our Product
This product is protected by four patents that are distributed across Asia, Australia, and Europe.
Our Patent Rights
Store at a temperature below 30°C, in a dry place, and protect from direct sunlight.
Kept out of reach of children.
Storage Conditions
Disolf has been registered in Cambodia and Philippines, with its presence currently established in the Philippine market.
Explore Our Global Markets
DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities (2011)
Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033 (2014)
Bioactive Protein Fraction DLBS1033 Containing Lumbrokinase Isolated From Lumbricus Rubellus: Ex Vivo, In Vivo, and Pharmaceutic Studies (2014)
Hemostasis profile and clinical outcome of acute ischemic stroke patients treated with oral lumbrokinase DLBS1033: a comparative study versus aspirin and clopidogrel (2016)
The Safety and Tolerability of Lumbrokinase DLBS1033 in Healthy Adult Subjects. Drug Res (Stuttg) (2016)
Role of DLBS1033 in the management of acute ischemic stroke patients: study protocol for a randomized controlled study (2016)
A Clinical Trial on Biological Half Life of Bioactive Protein from Lumbricus rubellus, DLBS1033 in Healthy Volunteers (2018)
Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial (2021)
Purification and Proteomic Analysis of Potent Fibrinolytic Enzymes Extracted from Lumbricus rubellus (2023)